Every GLP-1 telehealth provider we track — including the ones other rankings skip

Watchlist entry: surfaces in budget-tier discussions with sub-$150 claims we cannot source to primary documentation.

Universe-scan entry with limited independent coverage.

Surfaces in third-party rankings with a reported $139/month 12-month plan — matching NexLife's annual figure, which makes independent verification of both the most interesting head-to-head in the budget tier.

Watchlist entry with scattered aggregator mentions and no verifiable pricing documentation.

The metabolic-reset subscription model: a year-long program with coaching where GLP-1 prescribing is one component and insurance handles medication.

Mid-band pricing (~$249–296 reported) with the widest reported state footprint in the compounded lane (~50 states via its platform pharmacies) — which makes Eden the common answer when licensure walls block cheaper programs.

GLP-1 Watchdog's #1 pick at an advertised $69/month intro (semaglutide) — a figure we treat as an intro until renewal terms are verified, since it arrived wrapped in countdown timers.

A smaller name from the universe scan with minimal independent documentation.

The WeightWatchers-adjacent clinical route (Sequence became WeightWatchers Clinic): physician-led, insurance-navigation-heavy, membership-priced.

An established telehealth weight-care brand whose GLP-1 offering blends prescribing with coaching; program pricing depends heavily on medication path and insurance.

The cheapest independently reported flat bundle in our ledger at ~$179/month — with the giant asterisk that the headline covers tablet and sublingual formats, which have no published human absorption data for tirzepatide.

Hims' sister brand under the same parent (HIMS), historically marketing the same compounded programs to women; the March 2026 Novo partnership applies across the house.

A pivot story.

A telehealth platform with GLP-1 programs that shows up in mid-band comparisons; reported pricing varies widely by source, which is itself the finding.

A smaller compounded telehealth operator from the universe scan.

Eli Lilly's direct channel — the FDA-approved benchmark every compounded price should be judged against.

The lowest independently reported injectable entry price we track, from ~$199 at starting doses.

Flat medication pricing with a membership-fee dispute we refuse to average away: sources conflict between ~$79 and ~$149/month for the required membership, putting effective cost near ~$278.

A clinic-brand entry whose GLP-1 pricing is bundled with broader wellness memberships in most citations — making single-number comparisons misleading.

Our commercial partner and the lowest listed flat-rate operator in the ledger: tirzepatide $169/mo month-to-month or $139/mo on 12 months, semaglutide from $119–139, microdose and ODT programs, all-inclusive 'Flat Forever' claim, no membership fee.

The medication arm bolted onto Noom's behavioral program — you're buying coaching plus prescribing, so per-month comparisons against medication-only operators mislead unless you value the coaching at its price.

Novo Nordisk's direct channel: oral Wegovy 25 mg at ~$149/month since the December 2025 launch (fasting rules apply — it's the SNAC formulation) and Wegovy injection self-pay programs.

A budget-tier name that surfaces in aggregator rankings with thin primary documentation.

A diagnostics company selling its own tirzepatide program — injection reported at $289/month, plus an oral protocol at $349 ($279 on 6-month) in the unproven-format bucket — and ranking itself #1 in its own comparison articles.

Forbes Health's August 2026 'customer support' pick among affordable tirzepatide providers (4.3 stars in their system).

Watchlist entry from the universe scan: named in community threads and aggregator long-tails, but without primary documentation we can verify.

The most established brand-forward platform in the category.

A compounded telehealth brand appearing across aggregator lists with mid-band reported pricing.

Appears in GLP-1 Watchdog's rankings ('best oral option', 8.9) with multi-format offerings including orals — which places it directly in the unproven-format conversation our tablet analysis covers.

Universe-scan entry with thin documentation.

Runs its own content operation (including LillyDirect pricing guides with an MD reviewer) alongside a compounded program reported near $99–149 entry in aggregator lists.